Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

Signature(s)

Amount
€ 800,000,000
Countries
Sector(s)
Germany : € 800,000,000
Industry : € 800,000,000
Signature date(s)
13/01/2025 : € 300,000,000
26/11/2024 : € 500,000,000
Link to source

Summary sheet

Release date
2 December 2024
Status
Reference
Signed | 26/11/2024
20230583
Project name
Promoter - financial intermediary
BAYER PHARMACEUTICAL RDI
BAYER AG
Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
EUR 800 million
EUR 2525 million
Location
Sector(s)
Description
Objectives

The project will support Bayer, an EU-based promoter, in its Research & Development (R&D) activities concerning its Pharmaceutical business. In detail, R&D refers to its pharmaceutical product pipeline targeting unmet medical needs, in particular related to therapeutic areas of Cardiology, Oncology care, Ophthalmology, Women's Healthcare, Radiology as well as Cross-disease research platforms and other R&D project work.

The project supports an European promoter in its efforts to foster its competitive position in high value-added products by investing in R&D activities. It contributes to the targets of Horizon Europe priorities of strengthening the EU's scientific and technological foundations and European Research Area (ERA) and increasing innovation capacity, competitiveness, and the number of jobs in Europe. Moreover, the project corresponds to Article 309 point (c) Common interest, contributing to the PPG "Innovation, Digital and Human Capital RDI". The products developed as a result of the project will address unmet medical needs, positively supporting the European effort in advancing the Sustainable Development Goal SDG3, "Ensure healthy lives and promote well-being for all at all ages". As such, the project would also improve the possibilities of social inclusion of people suffering from debilitating diseases including neglected diseases as addressed under this project, therefore the social value of the project is considered to be positive.

Additionality and Impact

The project concerns a corporate project by a leading pharmaceutical company. The promoter is a knowledge-based company developing innovative therapies and treatment for life threatening diseases addressing unmet medical needs. With its continuous and relentless focus on R&D excellence the promoter is ranked among the 10 largest R&D investors in the EU and intends to continue its very high investments levels despite headwinds. The company's R&D intensity is above sector average contributing positively to the EU's 3% R&D intensity target. The Bank's financing will allow an EU R&D champion to continue improving its cutting-edge life science investments and development processes ensuring important benefits of bringing novel therapies to the patients in a timely manner. As such, the social value of the project is considered to be positive and over and above the financial return.


The Bank's contribution to the project is underpinned by a combination of advantageous terms, a meaningful loan amount as well as a signaling effect in terms of confidence in the business model, thereby facilitating the project's financing and full implementation.

Environmental aspects
Procurement

The R&D activities are expected to be carried out in existing facilities that are already used for the same purposes and that are not expected to change their scope due to the project. An Environmental Impact Assessment (EIA) is therefore not needed as per EIA Directive 2014/52/EU (amending Directive 2011/92/EU). The full environmental details will however be investigated by the Bank's services during the project due diligence.

The promoter has been assessed by the EIB as being a private company not being subject to EU rules on public procurement or concessions. However, if at the project appraisal, the EIB were to conclude that the promoter is subject to the EU public procurement legislation then the Bank would duly inform the Commission Services and would require the promoter to apply those rules.

Milestone
Under appraisal
Approved
Signed
21 March 2024
26 November 2024
Link to source
Other links

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

Documents

Environmental and Social Data Sheet (ESDS) - BAYER PHARMACEUTICAL RDI
Publication Date
14 Feb 2025
Document language
Main Topic
Lending
Document Number
241309013
Document Focus
Environmental Information
Project Number
20230583
Sector(s)
Regions
Countries
Publicly available
Download now
Other links

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

Related publications